Ken Griffin Genprex, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$0.19 - $0.37 $684 - $1,332	-3,600 Reduced 52.94%	3,200 $0
Q3 2023 Nov 14, 2023	SELL	$0.37 - $1.04 $1,665 - $4,680	-4,500 Reduced 39.82%	6,800 $2,000
Q2 2023 Aug 14, 2023	SELL	$0.74 - $1.1 $21,164 - $31,460	-28,600 Reduced 71.68%	11,300 $10,000
Q1 2023 May 15, 2023	BUY	$0.76 - $1.78 $8,056 - $18,868	10,600 Added 36.18%	39,900 $36,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $4,600 - $270,480	-4,600 Reduced 13.57%	29,300 $42,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $24,156 - $1.06 Million	-18,300 Reduced 35.06%	33,900 $48,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.